DK2076271T3 - Inhibering af koleratoksiner med galacto-oligosaccharider (GOS) - Google Patents

Inhibering af koleratoksiner med galacto-oligosaccharider (GOS)

Info

Publication number
DK2076271T3
DK2076271T3 DK07834613.7T DK07834613T DK2076271T3 DK 2076271 T3 DK2076271 T3 DK 2076271T3 DK 07834613 T DK07834613 T DK 07834613T DK 2076271 T3 DK2076271 T3 DK 2076271T3
Authority
DK
Denmark
Prior art keywords
gos
galacto
oligosaccharides
inhibition
nutritional
Prior art date
Application number
DK07834613.7T
Other languages
Danish (da)
English (en)
Inventor
Haydn Robert Sinclair
Slegte Jaap De
Gijsbertus Klarenbeek
Original Assignee
Friesland Brands Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friesland Brands Bv filed Critical Friesland Brands Bv
Application granted granted Critical
Publication of DK2076271T3 publication Critical patent/DK2076271T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK07834613.7T 2006-10-02 2007-10-01 Inhibering af koleratoksiner med galacto-oligosaccharider (GOS) DK2076271T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06076810 2006-10-02
PCT/NL2007/050475 WO2008041843A1 (en) 2006-10-02 2007-10-01 Inhibition of cholera toxins by galatooligosaccharides (gos)

Publications (1)

Publication Number Publication Date
DK2076271T3 true DK2076271T3 (da) 2012-01-16

Family

ID=37533486

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07834613.7T DK2076271T3 (da) 2006-10-02 2007-10-01 Inhibering af koleratoksiner med galacto-oligosaccharider (GOS)

Country Status (10)

Country Link
US (1) US8202842B2 (enExample)
EP (1) EP2076271B1 (enExample)
JP (1) JP2010505822A (enExample)
AT (1) ATE524190T1 (enExample)
DK (1) DK2076271T3 (enExample)
ES (1) ES2373592T3 (enExample)
PL (1) PL2076271T3 (enExample)
PT (1) PT2076271E (enExample)
SI (1) SI2076271T1 (enExample)
WO (1) WO2008041843A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
FR2907687B1 (fr) * 2006-10-30 2008-12-26 Applexion Procede de purification de sialyllactose par chromatographie
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
KR20170053733A (ko) 2009-02-24 2017-05-16 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
JP2012520325A (ja) † 2009-03-13 2012-09-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プレバイオティックオリゴ糖
US20110189342A1 (en) * 2010-02-01 2011-08-04 Jeong Hea-Seok High-purity galactooligosaccharides and uses thereof
NL2007931C2 (en) 2011-12-07 2013-06-10 Friesland Brands Bv Methods for providing sialylated oligosaccharides and products obtainable thereby.
WO2015095747A1 (en) 2013-12-20 2015-06-25 Abbott Laboratories Oral rehydration composition with oligosaccharides
EP3530743A1 (en) 2018-02-21 2019-08-28 Cambridge Glycoscience Ltd Method of production
AU2019321182B2 (en) 2018-08-15 2025-01-09 Cambridge Glycoscience Ltd. Novel compositions, their use, and methods for their formation
CA3108735A1 (en) 2018-09-06 2020-03-12 Frieslandcampina Nederland B.V. Bifidogenic hypoallergenic gos compositions and methods for providing the same involving beta-galactosidase from a strain of lactobacillus delbrueckii ssp bulgaricus
KR102874614B1 (ko) * 2018-11-08 2025-10-22 디에스엠 아이피 어셋츠 비.브이. 위장 대사물질을 조절하는 방법
US11911405B2 (en) * 2018-11-08 2024-02-27 Dsm Ip Assets B.V. Methods of selectively modulating gastrointestinal microbial growth
EP4013240A1 (en) 2019-08-16 2022-06-22 Cambridge Glycoscience Ltd Methods of treating biomass to produce oligosaccharides and related compositions
CN115279208B (zh) 2019-12-12 2024-12-17 剑桥糖质科学有限公司 低糖多相食品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0614870B2 (ja) * 1986-12-15 1994-03-02 株式会社ヤクルト本社 ガラクトオリゴ糖の製造法
NZ222902A (en) 1986-12-15 1990-08-28 Yakult Honsha Kk Method for producing galactooligosaccharide
ZA991410B (en) 1998-02-23 1999-10-06 Synsorb Biotech Inc Compounds and methods for the treatment of bacterial dysentry using antibiotics and toxin binding oligosaccharide compositions.
US6630452B2 (en) * 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
FR2838452B1 (fr) 2002-04-10 2004-07-09 Eurodia Ind Procede de production en continu de galacto oligosaccharides
GB0229015D0 (en) 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
GB0308104D0 (en) * 2003-04-08 2003-05-14 Novartis Nutrition Ag Organic compounds
MXPA05010349A (es) 2003-06-30 2006-03-08 Clasado Inc Composicion novedosa de galactooligosacaridos y preparacion de la misma.
JP4847321B2 (ja) 2003-07-04 2011-12-28 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション 金属化合物を製造するための方法および装置
US20070196890A1 (en) 2003-10-02 2007-08-23 Jelena Vulevic Prebiotic effect analysis

Also Published As

Publication number Publication date
PL2076271T3 (pl) 2012-02-29
US8202842B2 (en) 2012-06-19
JP2010505822A (ja) 2010-02-25
ATE524190T1 (de) 2011-09-15
ES2373592T3 (es) 2012-02-06
EP2076271A1 (en) 2009-07-08
PT2076271E (pt) 2011-12-02
WO2008041843A1 (en) 2008-04-10
EP2076271B1 (en) 2011-09-14
US20100069322A1 (en) 2010-03-18
SI2076271T1 (sl) 2011-12-30

Similar Documents

Publication Publication Date Title
DK2076271T3 (da) Inhibering af koleratoksiner med galacto-oligosaccharider (GOS)
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
WO2004103294A3 (en) Methods and compositions for the prevention and treatment of sepsis
TW200740849A (en) Dual variable domain immunoglobulin and uses thereof
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
BRPI0616960B8 (pt) uso de lactobacilo para o tratamento de infecções virais
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2006128032A3 (en) Compositions and methods for the prevention and treatment of conditions associated with inflammation
WO2008024188A8 (en) Dual variable domain immunoglobulin and uses thereof
EP2982696A3 (en) Treatment of acute lymphoblastic leukemia
WO2010023422A8 (en) Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
ATE375164T1 (de) Endotoxin-bindung durch milchsäurebakterien und bifidobacteria
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
BR112012008238A2 (pt) métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais.
BRPI0722054A2 (pt) Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
EP2348854A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING
ATE537819T1 (de) Nutrazeutische zusammensetzungen zur behandlung von muskelschwund
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
WO2007100765A3 (en) Lysozyme-modified probiotic components and uses thereof
BRPI0808823A2 (pt) composição e método para tratar, reduzir, melhorar ou prevenir uma infecção.
ATE542832T1 (de) Nahrungsmittel zur inhibierung der osteoclastbildung
WO2006071456A3 (en) Inhibition of hsp27 phosphorylation for treatment of blistering disorders
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
WO2008063853A3 (en) Cancer treatment method